Pall invests in virus inactivation technology:
This article was originally published in Clinica
Pall Corporation has released $3 million in a milestone payment to VI Technologies as it enters Phase I clinical trials on its proprietary INACTINE red blood cell inactivation technology. VI Technologies, of Melville, New York, estimates that the potential market for virally-inactivated red blood cells could exceed $2 billion annually.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.